Bayer Healthcare, part of Bayer AG, of Leverkusen, Germany, said it plans to build a $100 million facility in Berkeley, Calif., for product testing, which will support the next-generation treatments for those with hemophilia A. The company already has a manufacturing facility in Berkeley and its U.S. research hub, the U.S. Innovation Center in San Francisco.
Daiichi Sankyo Co. Ltd., of Tokyo, said Swissmedic, the regulatory authority of Switzerland, approved Lixiana (edoxaban), an oral, once-daily selective factor Xa inhibitor, to prevent stroke and systemic embolism in adults with nonvalvular atrial fibrillation. In addition, the company said the drug has obtained marketing authorization in Switzerland for adults with venous thromboembolism including deep vein thrombosis and pulmonary embolism, following prior treatment with fractionated or unfractionated heparin for five days, as well as to prevent the recurrence of VTE.